Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Bausch Health (NYSE/TSX:BHC) and its GI business, Salix Pharmaceuticals, along with major health organizations, are commemorating the second annual Opioid-Induced Constipation (OIC) Awareness Day on December 5, 2024. The initiative aims to raise awareness about OIC, a common side effect of opioid treatment.
According to statistics, approximately 21% of U.S. adults experienced chronic pain in 2021, with 22% of chronic pain patients receiving opioid prescriptions in 2019. To support the cause, Salix has updated the OICAwarenessDay.com website with resources for healthcare providers, patients, and caregivers. The campaign includes partnerships with influencers, a content program with Chronicon, and social media engagement using hashtags #OICAwarenessDay and #vOICesOfOIC.
Bausch Health (NYSE/TSX:BHC) e la sua divisione GI, Salix Pharmaceuticals, insieme a importanti organizzazioni sanitarie, celebrano il secondo annuale Giorno della Consapevolezza sulla Costipazione Indotta da Oppiacei (OIC) il 5 dicembre 2024. L'iniziativa mira a sensibilizzare riguardo all'OIC, un effetto collaterale comune dei trattamenti oppiacei.
Secondo le statistiche, circa il 21% degli adulti negli Stati Uniti ha sofferto di dolore cronico nel 2021, con il 22% dei pazienti con dolore cronico che ha ricevuto prescrizioni per oppiacei nel 2019. Per sostenere questa causa, Salix ha aggiornato il sito OICAwarenessDay.com con risorse per fornitori di assistenza sanitaria, pazienti e caregiver. La campagna comprende collaborazioni con influencer, un programma di contenuti con Chronicon e coinvolgimento sui social media attraverso gli hashtag #OICAwarenessDay e #vOICesOfOIC.
Bausch Health (NYSE/TSX:BHC) y su negocio GI, Salix Pharmaceuticals, junto con importantes organizaciones de salud, están conmemorando el segundo Día de Conciencia sobre la Constipación Inducida por Opioides (OIC) el 5 de diciembre de 2024. La iniciativa busca aumentar la conciencia sobre la OIC, un efecto secundario común del tratamiento con opioides.
De acuerdo con las estadísticas, aproximadamente el 21% de los adultos en EE. UU. experimentaron dolor crónico en 2021, y el 22% de los pacientes con dolor crónico recibió recetas de opioides en 2019. Para apoyar la causa, Salix ha actualizado el sitio web OICAwarenessDay.com con recursos para proveedores de salud, pacientes y cuidadores. La campaña incluye asociaciones con influencers, un programa de contenido con Chronicon y participación en redes sociales utilizando los hashtags #OICAwarenessDay y #vOICesOfOIC.
바우슈 헬스(Bausch Health) (NYSE/TSX:BHC)와 그 GI 사업부인 살릭스 제약(Salix Pharmaceuticals)는 주요 건강 기관들과 함께 2024년 12월 5일에 두 번째 오피오이드 유발 변비(OIC) 인식의 날을 기념하고 있습니다. 이 이니셔티브는 오피오이드 치료의 일반적인 부작용인 OIC에 대한 인식을 높이는 것을 목표로 합니다.
통계에 따르면, 2021년 미국 성인의 약 21%가 만성 통증을 경험했으며, 2019년 만성 통증 환자의 22%가 오피오이드 처방을 받았습니다. 이 cause를 지원하기 위해 살릭스는 의료 제공자, 환자 및 보호자를 위한 자료로 OICAwarenessDay.com 웹사이트를 업데이트했습니다. 이 캠페인에는 인플루언서와의 협력, Chronicon와 함께하는 콘텐츠 프로그램 및 해시태그 #OICAwarenessDay 및 #vOICesOfOIC를 사용한 소셜 미디어 참여가 포함됩니다.
Bausch Health (NYSE/TSX:BHC) et son activité GI, Salix Pharmaceuticals, en collaboration avec des organisations de santé majeures, célèbrent le deuxième Jour de Sensibilisation à la Constipation Induite par les Opioïdes (OIC) le 5 décembre 2024. L'initiative vise à sensibiliser sur l'OIC, un effet secondaire courant des traitements aux opioïdes.
Selon les statistiques, environ 21 % des adultes américains ont souffert de douleurs chroniques en 2021, avec 22 % des patients souffrant de douleurs chroniques recevant des prescriptions d'opioïdes en 2019. Pour soutenir cette cause, Salix a mis à jour le site OICAwarenessDay.com avec des ressources pour les prestataires de soins de santé, les patients et les aidants. La campagne comprend des partenariats avec des influenceurs, un programme de contenu avec Chronicon et un engagement sur les réseaux sociaux en utilisant les hashtags #OICAwarenessDay et #vOICesOfOIC.
Bausch Health (NYSE/TSX:BHC) und sein GI-Geschäft, Salix Pharmaceuticals, gemeinsam mit wichtigen Gesundheitsorganisationen, gedenken des zweiten jährlichen Tages der Sensibilisierung für opioidinduzierte Verstopfung (OIC) am 5. Dezember 2024. Die Initiative hat das Ziel, das Bewusstsein für OIC zu schärfen, eine häufige Nebenwirkung der Opioidbehandlung.
Statistiken zufolge erlebten etwa 21 % der Erwachsenen in den USA im Jahr 2021 chronische Schmerzen, wobei 22 % der chronischen Schmerzpatienten im Jahr 2019 Opioidverschreibungen erhielten. Um die Sache zu unterstützen, hat Salix die Webseite OICAwarenessDay.com mit Ressourcen für Gesundheitsdienstleister, Patienten und Pflegepersonen aktualisiert. Die Kampagne umfasst Partnerschaften mit Influencern, ein Content-Programm mit Chronicon und die aktive Teilnahme in sozialen Medien mit den Hashtags #OICAwarenessDay und #vOICesOfOIC.
- None.
- None.
LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC.
"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."
In 2021, about
"We're deeply committed to bringing attention to those affected by OIC on this annual awareness day," said Ceciel Rooker, President and Executive Director of IFFGD. "Empowering patients to speak openly about their symptoms is crucial. It's the first step toward helping to ensure they receive the appropriate treatment, and not suffer in silence."
In honor of the second annual OIC Awareness Day, Salix has refreshed the OICAwarenessDay.com website to offer valuable information and resources for healthcare providers, patients, and caregivers, addressing the causes, symptoms, and management of OIC. Additionally, Salix has partnered with influencers to spread the word online using the hashtag #vOICesOfOIC, launched a content program with Chronicon, a global community for people with chronic illnesses, and shared posts across their social media channels to increase awareness about OIC.
"We're honored to be a part of OIC Awareness Day for the second year in a row," said Nicole Hemmenway, CEO of USPF. "By continuing to raise awareness about this condition, we aim to educate both healthcare providers and patients about OIC, a commonly overlooked side effect."
For more information on OIC and to learn how you can join the #OICAwarenessDay movement, please visit www.OICAwarenessDay.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
About The U.S. Pain Foundation
The U.S. Pain Foundation is a 501(c)(3) nonprofit with a mission to empower, educate, connect, and advocate for individuals living with chronic illnesses and serious injuries that cause pain, as well as their care partners and clinicians. Through its multiple programs and services, the organization works to elevate the patient voice, increase disease-state education, improve pain care through policy change, expand outreach to underserved and marginalized communities, and provide comprehensive resources to ensure individuals are supported and empowered along their journeys. Learn more at uspainfoundation.org.
About The International Foundation for Gastrointestinal Disorders
The International Foundation for Gastrointestinal Disorders (IFFGD) is a nonprofit education and research organization dedicated to improving the lives of people affected by chronic gastrointestinal illnesses. Founded in 1991, IFFGD helps improve patient outcomes by enhancing awareness, improving education, and supporting and encouraging research into treatments and cures for chronic digestive disorders.
About The American Chronic Pain Association
The American Chronic Pain Association (ACPA) is a non-profit, 501(c) (3) organization. Our Mission is to facilitate peer support, education, hope, and motivation for individuals living with pain and those treating pain conditions. We strive to raise awareness among the health care community, policymakers, and the public at large about issues of living with physical and emotional pain. Our vision is to motivate those with pain conditions to seek quality care, to optimize healthcare office visits, and to prevent chronic disease.
Forward-looking Statements
This news release may contain forward-looking statements about the future performance of Bausch Health which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
###
Investor Contact: |
| Media Contact: |
Garen Sarafian |
| Katie Savastano |
| ||
877-281-6642 (toll-free) |
| (908) 569-3692 |
SOURCE: Bausch Health Companies Inc.
View the original press release on accesswire.com
FAQ
When is Opioid-Induced Constipation Awareness Day 2024 for Bausch Health (BHC)?
What percentage of US adults with chronic pain were treated with opioids according to BHC's report?
What initiatives has Bausch Health (BHC) launched for OIC Awareness Day 2024?
Which organizations are partnering with Bausch Health (BHC) for OIC Awareness Day 2024?
